20-F Filing

RENALYTIX PLC CIK: 1811115 FY 2021

Filing Information

Form Type	20-F
Accession Number	`0001193125-21-303600`
Period End Date	20210630
Filing Date	20211021
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	d186302d20f_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 50 Cash Flow Statement 96 Stockholders Equity 21

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Common stock par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.00	GBP	Point-in-time
Common stock par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.00	GBP	Point-in-time
Common stock shares authorized	`CommonStockSharesAuthorized`	76.46M	shares	Point-in-time
Common stock shares authorized	`CommonStockSharesAuthorized`	62.44M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$65.13M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
Common stock shares issued	`CommonStockSharesIssued`	72.20M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$13.29M	USD	Point-in-time
Common stock shares issued	`CommonStockSharesIssued`	59.42M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.20M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	-	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$982.00K	USD	Point-in-time
Common stock shares outstanding	`CommonStockSharesOutstanding`	59.42M	shares	Point-in-time
Short-term investments	`ShortTermInvestments`	$994.00K	USD	Point-in-time
Common stock shares outstanding	`CommonStockSharesOutstanding`	72.20M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$594.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$551.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$993.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$227.00K	USD	Point-in-time
Note receivable from Kantarocurrent	`NotesReceivableRelatedPartiesCurrent`	$75.00K	USD	Point-in-time
Receivable from affiliates	`DueFromAffiliateCurrent`	$18.00K	USD	Point-in-time
Receivable from affiliates	`DueFromAffiliateCurrent`	$1.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$66.79M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.84M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.42M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$2.49M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.66M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$278.00K	USD	Point-in-time
Investment in VericiDx	`InvestmentsInAndAdvancesToAffiliatesAtFairValue`	$9.29M	USD	Point-in-time
Investment in Kantaro	`InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures`	$1.94M	USD	Point-in-time
Note receivable from Kantarononcurrent	`NotesReceivableRelatedPartiesNoncurrent`	$83.00K	USD	Point-in-time
Deferred offering costs	`DeferredOfferingCostsNonCurrent`	-	USD	Point-in-time
Deferred offering costs	`DeferredOfferingCostsNonCurrent`	$2.36M	USD	Point-in-time
Deferred offering costs	`DeferredOfferingCostsNonCurrent`	-	USD	Point-in-time
Total assets	`Assets`	$9.70M	USD	Point-in-time
Total assets	`Assets`	$20.88M	USD	Point-in-time
Total assets	`Assets`	$78.58M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$317.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.40M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.22M	USD	Point-in-time
Accounts payable-related party	`AccountsPayableRelatedPartiesCurrent`	$361.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$683.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$4.60M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$832.00K	USD	Point-in-time
Accrued expensesrelated party	`AccruedExpensesRelatedPartyCurrent`	$224.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$122.00K	USD	Point-in-time
Note payablecurrent	`ShortTermBankLoansAndNotesPayable`	$120.00K	USD	Point-in-time
Payable to affiliatecurrent	`DueToAffiliateCurrent`	$350.00K	USD	Point-in-time
Payable to affiliatecurrent	`DueToAffiliateCurrent`	$271.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.06M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.29M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.15M	USD	Point-in-time
Payable to affiliatenoncurrent	`DueToAffiliateNoncurrent`	$1.54M	USD	Point-in-time
Note payablenoncurrent	`NotesPayableToBankNoncurrent`	$135.00K	USD	Point-in-time
Other liabilities	`OtherLiabilitiesNoncurrent`	$53.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$7.12M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.15M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.97M	USD	Point-in-time
Commitments and contingencies (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, 0.0025 par value per share: 76,463,244 and 62,444,992 shares authorized at June 30, 2021 and June 30, 2020, respectively; 72,197,286 and 59,416,134 shares issued and outstanding at June 30, 2021 and June 30, 2020, respectively	`CommonStockValue`	$220.00K	USD	Point-in-time
Ordinary shares, 0.0025 par value per share: 76,463,244 and 62,444,992 shares authorized at June 30, 2021 and June 30, 2020, respectively; 72,197,286 and 59,416,134 shares issued and outstanding at June 30, 2021 and June 30, 2020, respectively	`CommonStockValue`	$179.00K	USD	Point-in-time
Ordinary shares, 0.0025 par value per share: 76,463,244 and 62,444,992 shares authorized at June 30, 2021 and June 30, 2020, respectively; 72,197,286 and 59,416,134 shares issued and outstanding at June 30, 2021 and June 30, 2020, respectively	`CommonStockValue`	$162.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$52.08M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$69.65M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$150.41M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$8.28M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.20M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-822.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-52.72M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-42.87M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-87.44M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$15.91M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$-502.00K	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$71.46M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$8.55M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$78.58M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$9.70M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$20.88M	USD	Point-in-time

Income Statement 50 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	$1.49M	USD	Annual
Cost of revenue	`CostOfRevenue`	$858.00K	USD	Annual
Gross profit	`GrossProfit`	$633.00K	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$35.29M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$10.04M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$4.32M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$4.57M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$2.74M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$5.75M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$23.48M	USD	Annual
Performance of contract liability to affiliate	`PerformanceOfContractLiabilityToAffiliate`	$970.00K	USD	Annual
Total operating expenses	`OperatingExpenses`	$-32.55M	USD	Annual
Total operating expenses	`OperatingExpenses`	$-10.31M	USD	Annual
Total operating expenses	`OperatingExpenses`	$-42.34M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-31.92M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-10.31M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-42.34M	USD	Annual
Equity in losses of affiliate	`IncomeLossFromEquityMethodInvestments`	$-2.11M	USD	Annual
Equity in losses of affiliate	`IncomeLossFromEquityMethodInvestments`	$-63.00K	USD	Annual
Foreign currency (loss)/gain	`ForeignCurrencyTransactionGainLossBeforeTax`	$20.00K	USD	Annual
Foreign currency (loss)/gain	`ForeignCurrencyTransactionGainLossBeforeTax`	$-8.77M	USD	Annual
Foreign currency (loss)/gain	`ForeignCurrencyTransactionGainLossBeforeTax`	$245.00K	USD	Annual
Fair value adjustment to VericiDx investment	`FairValueAdjustmentToVericidxInvestment`	$-6.48M	USD	Annual
Gain on loan extinguishment	`GainsLossesOnExtinguishmentOfDebt`	$255.00K	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$726.00K	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$289.00K	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$18.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-9.84M	USD	Annual
Net loss	`NetIncomeLoss`	$-42.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-35.34M	USD	Annual
Net loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$611.00K	USD	Annual
Net loss attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-42.30M	USD	Annual
Net loss attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-34.73M	USD	Annual
Net loss attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-9.84M	USD	Annual
Foreign exchange translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$9.50M	USD	Annual
Foreign exchange translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-378.00K	USD	Annual
Foreign exchange translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-826.00K	USD	Annual
Comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-43.13M	USD	Annual
Comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-10.22M	USD	Annual
Comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-25.84M	USD	Annual
Comprehensive loss attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-72.00K	USD	Annual
Comprehensive loss attributable to Renalytix AI	`ComprehensiveIncomeNetOfTax`	$-43.13M	USD	Annual
Comprehensive loss attributable to Renalytix AI	`ComprehensiveIncomeNetOfTax`	$-10.22M	USD	Annual
Comprehensive loss attributable to Renalytix AI	`ComprehensiveIncomeNetOfTax`	$-25.76M	USD	Annual
Net loss per ordinary sharebasic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.49	USD	Annual
Net loss per ordinary sharebasic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.99	USD	Annual
Net loss per ordinary sharebasic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.17	USD	Annual
Weighted average ordinary sharesbasic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	59.08M	shares	Annual
Weighted average ordinary sharesbasic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	42.56M	shares	Annual
Weighted average ordinary sharesbasic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	71.48M	shares	Annual

Cash Flow Statement 96 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-9.84M	USD	Annual
Net loss	`NetIncomeLoss`	$-42.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-35.34M	USD	Annual
Non-cash in-process research and development charge	`ResearchAndDevelopmentInProcess`	$35.29M	USD	Annual
Gain on deconsolidation of VericiDx	`DeconsolidationGainOrLossAmount`	$46.00K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$70.00K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$282.00K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$31.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$2.66M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$525.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$1.16M	USD	Annual
Gain on loan	`GainLossOnSalesOfLoansNet`	$-255.00K	USD	Annual
Realized gain on short-term investments	`DebtAndEquitySecuritiesRealizedGainLoss`	$18.00K	USD	Annual
Realized gain on short-term investments	`DebtAndEquitySecuritiesRealizedGainLoss`	$128.00K	USD	Annual
Realized gain on short-term investments	`DebtAndEquitySecuritiesRealizedGainLoss`	$24.00K	USD	Annual
Equity losses in affiliate, including related impairments	`IncomeLossFromEquityMethodInvestments`	$-2.11M	USD	Annual
Equity losses in affiliate, including related impairments	`IncomeLossFromEquityMethodInvestments`	$-63.00K	USD	Annual
Reversal of Kantaro Liability	`ReversalOfKantaroLiability`	$495.00K	USD	Annual
Fair value adjustment to VericiDx investment	`FairValueAdjustmentToVericidxInvestment`	$-6.48M	USD	Annual
Unrealized foreign exchange loss (gain)	`ForeignCurrencyTransactionGainLossUnrealized`	$213.00K	USD	Annual
Unrealized foreign exchange loss (gain)	`ForeignCurrencyTransactionGainLossUnrealized`	$-5.54M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$594.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$197.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$710.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$325.00K	USD	Annual
Related party receivable	`IncreaseDecreaseInDueFromRelatedParties`	$-17.00K	USD	Annual
Related party receivable	`IncreaseDecreaseInDueFromRelatedParties`	$18.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$303.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$782.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$355.00K	USD	Annual
Accrued expensesrelated party	`IncreaseDecreaseInAccruedExpensesRelatedParty`	$585.00K	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-456.00K	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$4.35M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$221.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$122.00K	USD	Annual
Payable to affiliate	`IncreaseDecreaseInDueToAffiliates`	$-970.00K	USD	Annual
Payable to affiliate	`IncreaseDecreaseInDueToAffiliates`	$-185.00K	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$53.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.52M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.16M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-28.40M	USD	Annual
Note receivablerelated party	`ProceedsFromNotesReceivableRelatedParty`	$-83.00K	USD	Annual
Note receivablerelated party	`ProceedsFromNotesReceivableRelatedParty`	$-167.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$804.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$773.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$309.00K	USD	Annual
Software development costs	`PaymentsToDevelopSoftware`	$749.00K	USD	Annual
Software development costs	`PaymentsToDevelopSoftware`	$427.00K	USD	Annual
Purchase of short-term investments	`PaymentsToAcquireShortTermInvestments`	$21.26M	USD	Annual
Purchase of short-term investments	`PaymentsToAcquireShortTermInvestments`	$4.97M	USD	Annual
Proceeds from short-term investments	`ProceedsFromSaleOfShortTermInvestments`	$21.40M	USD	Annual
Proceeds from short-term investments	`ProceedsFromSaleOfShortTermInvestments`	$1.00M	USD	Annual
Proceeds from short-term investments	`ProceedsFromSaleOfShortTermInvestments`	$4.00M	USD	Annual
Decrease in cash (VericiDx deconsolidation)	`CashDivestedFromDeconsolidation`	$62.00K	USD	Annual
Acquired in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$11.02M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-12.30M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.17M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-751.00K	USD	Annual
Gross proceeds from the issuance of ordinary shares, net of underwriting fees	`GrossProceedsFromTheIssuanceOfOrdinarySharesNetOfUnderwritingFees`	$79.18M	USD	Annual
Gross proceeds from the issuance of ordinary shares	`ProceedsFromIssuanceOfCommonStock`	$29.11M	USD	Annual
Gross proceeds from the issuance of ordinary shares	`ProceedsFromIssuanceOfCommonStock`	$17.28M	USD	Annual
Payment of offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$1.59M	USD	Annual
Payment of offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$2.31M	USD	Annual
Payment of offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$1.29M	USD	Annual
Payment from related-party notes	`ProceedsFromRelatedPartyDebt`	$633.00K	USD	Annual
Proceeds from the issuance of ordinary shares under employee share purchase plan	`ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan`	$111.00K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$252.00K	USD	Annual
Proceeds from PPP Loan	`ProceedsFromIssuanceOfOtherLongTermDebt`	$255.00K	USD	Annual
Repayment of related-party notes	`RepaymentsOfRelatedPartyDebt`	$1.07M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$15.94M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$77.24M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$27.38M	USD	Annual
Effect of exchange rate changes on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$3.75M	USD	Annual
Effect of exchange rate changes on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-808.00K	USD	Annual
Effect of exchange rate changes on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-150.00K	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$5.09M	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$8.12M	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$51.84M	USD	Annual
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$65.13M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$13.29M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$8.20M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$65.13M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$13.29M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$8.20M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$21.00K	USD	Annual
Ordinary shares issued to acquire Joslin license	`StockIssued1`	$24.29M	USD	Annual
Financing costs in accounts payable and accrued expenses	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	$450.00K	USD	Annual
Financing costs in accounts payable and accrued expenses	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	$1.63M	USD	Annual
Software development costs in accounts payable and accrued expenses	`SoftwareDevelopmentCostsIncurredButNotPaid`	$177.00K	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$56.00K	USD	Annual
Reclassification of note receivable in Kantaro to Investment in Kantaro	`ReclassificationOfNoteReceivableInKantaroToInvestmentInKantaro`	$175.00K	USD	Annual
Deemed distribution of VericiDx ordinary shares	`DeemedDistributionOfOrdinarySharesNonCashTransaction`	$75.00K	USD	Annual
Conversion of VericiDx note receivable into VericiDx ordinary shares	`ConversionOfNotesReceivableIntoOrdinaryShares`	$2.56M	USD	Annual
Fair value of services exchanged for equity method investment of which services are recorded as the payable to affiliate	`FairValueOfServicesExchangedForEquityMethodInvestment`	$2.00M	USD	Annual

Stockholders Equity 21 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquity`	$15.91M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$-502.00K	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$71.46M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$8.55M	USD	Point-in-time
Deconsolidation of Verici	`NoncontrollingInterestDecreaseFromDeconsolidation`	$2.30M	USD	Annual
Shares issued under the employee share purchase plan (Value)	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$111.00K	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$1.16M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$525.00K	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$2.66M	USD	Annual
Exercise of stock options (Value)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$252.00K	USD	Annual
Exercise of stock options (Shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	150,000.00	shares	Annual
Currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$9.43M	USD	Annual
Currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-378.00K	USD	Annual
Currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-826.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-9.84M	USD	Annual
Net loss	`NetIncomeLoss`	$-42.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-35.34M	USD	Annual
Ending balance	`StockholdersEquity`	$15.91M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$-502.00K	USD	Point-in-time
Ending balance	`StockholdersEquity`	$71.46M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$8.55M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.